Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 13;39(7):107.
doi: 10.1007/s12032-022-01743-7.

Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management

Alfredo Tartarone  1 , Rosa Lerose  2 , Marina Tartarone  3
Affiliations
Review

Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management

Alfredo Tartarone et al. Med Oncol. .

Abstract

Non-metastatic castration-resistant prostate cancer (nmCRPC) indicates a condition characterized by the progression of the prostate-specific antigen without radiographic evidence of distant metastasis on conventional imaging during androgen deprivation therapy (ADT). Recently, 3 phase III trials have shown that the addition of next-generation androgen-receptor inhibitors (ARIs) apalutamide, darolutamide, and enzalutamide to ADT allows patients with high-risk nmCRPC to delay the appearance of metastasis and to obtain long-term clinical benefits. However, the lack of head-to head comparison makes it difficult to choose one among these agents. We reviewed the literature and explained the rationale of the possible therapeutic choices. In any case, the availability of novel ARIs means that patients with nmCRPC have now a new effective treatment option that provides them a renewed hope.

Keywords: Apalutamide; Darolutamide; Enzalutamide; Non-metastatic castration-resistant prostate cancer (nmCRPC).

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. - DOI
    1. von Eyben FE, Kairemo K, Paller C, Hoffmann MA, Paganelli G, Virgolini I, Roviello G. 177Lu-PSMA radioligand therapy is favorable as third-line treatment of patients with metastatic castration-resistant prostate cancer. A systematic review and network meta-analysis of randomized controlled trials. Biomedicines. 2021;9:1042. - DOI
    1. National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN guidelines). Prostate cancer, version 3.2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.Accessed 1 Feb 2022.
    1. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408–18. - DOI
    1. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79:150–8. - DOI

MeSH terms

LinkOut - more resources